Modeling of drug diffusion in a solid tumor leading to tumor cell death by Rahman, Aminur et al.
Modeling of drug diffusion in a solid tumor leading to
tumor cell death
Aminur Rahman∗†, Souparno Ghosh†, Ranadip Pal‡
Abstract
It has been shown recently that changing the fluidic properties of a drug can improve
its efficacy in ablating solid tumors. We develop a modeling framework for tumor
ablation, and present the simplest possible model for drug diffusion in a spherical tumor
with leaky boundaries and assuming cell death eventually leads to ablation of that cell
effectively making the two quantities numerically equivalent. The death of a cell after
a given exposure time depends on both the concentration of the drug and the amount
of oxygen available to the cell. Higher oxygen availability leads to cell death at lower
drug concentrations. It can be assumed that a minimum concentration is required for
a cell to die, effectively connecting diffusion with efficacy. The concentration threshold
decreases as exposure time increases, which allows us to compute dose-response curves.
Furthermore, these curves can be plotted at much finer time intervals compared to that
of experiments, which is used to produce a dose-threshold-response surface giving an
observer a complete picture of the drug’s efficacy for an individual. In addition, since
the diffusion, leak coefficients, and the availability of oxygen is different for different
individuals and tumors, we produce artificial replication data through bootstrapping
to simulate error. While the usual data-driven model with Sigmoidal curves use 12
free parameters, our mechanistic model only has two free parameters, allowing it to be
open to scrutiny rather than forcing agreement with data. Even so, the simplest model
in our framework, derived here, shows close agreement with the bootstrapped curves,
and reproduces well established relations, such as Haber’s rule.
Keywords: Cancer, diffusion, tumor ablation, numerical simulations
PACS numbers: 87.19.xj, 87.15.Vv, 87.85.Tu
1 Introduction
Historically, cancer has been treated using either generic-global drugs or by cutting away
the infected cells via surgery. While success rates have increased, these types of treatments
tend to have unwanted side-effects and are often quite expensive. This necessitates a new
paradigm for cancer treatment. In recent years there has been a shift towards developing
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individualized and targeted drug therapy [1, 2]. However, there are still many technical
and financial hurdles [3] to overcome before truly personalized medicine can be implemented
in real-life situations. In an effort to alleviate these hurdles, data analysis techniques with
statistical models have been employed [4]. With enough accurate data these models are
able to make remarkable predictions, however one cannot expect the patient specific data to
always be available and accurate. Furthermore, the mechanisms driving the phenomena are
not captured in these statistical models. A reliable mechanistic modeling framework may
alleviate the financial hurdles by simulating various treatment options, based on the physical
rather than statistical properties of a patient’s tumor, before administering drugs. While
data analysis has yielded promising results and should still be employed whenever possible,
mechanistic models serve as another weapon in the fight against cancer.
In the seminal work of Sugiura et al. [5] it was shown that ethanol can successfully
deteriorate malignant tissue. In fact, Ryu et al. [6] showed a comparable survival rate
to surgery in a statistical survey of hepatocellular carcinoma patients treated with ethanol
injections. As with any type of treatment, safety supersedes efficacy. An early work on
the safety of injecting ethanol into parathyroid tumors was conducted by Solbiati et al.
[7]. For the past decade there have been numerous studies on the safety and efficacy of
ethanol ablation for different types of tumors [8, 9, 10, 11, 12]. Some major drawbacks of
the technique include the need for multiphase treatments, large amounts of fluid, and the
rapid escape of ethanol in non-capsulated tumors [13]. Traditionally these drawbacks were
greater for larger tumors, but more recently it has been shown by Kuang et al. [11] that
a single-session high-dose ethanol injection can ablate hepatocellular carcinoma tumors of
diameters up to 5 cm.
Recently, Morhard et al. [13] developed a new method employing ethyl cellulose for which
single-phase small-volume treatments suffice to trigger ablation. Their goal is to maximize
distribution of the ethanol throughout the tumor while minimizing the necessary solution
volume. In essence, by changing the fluidic properties of the drug, they are able to increase
efficacy and decrease toxicity – the goal of cancer treatments. While this type of optimization
of fluidic properties has only been used with ethanol injections, one may see the potential of
using it for other drugs as well. After all, there is a wide variety of drug injection therapies
[14, 15, 16].
Although it may seem obvious that drug transport occurs as a diffusive process, it is still
worth noting that there is an abundance of drug diffusion models. Recent review articles have
discussed diffusion-based models of drug distribution from the blood stream into solid tumors
[17, 18]. In [18], Kim et al. advocate integrating mechanistic models with clinical data to
improve understanding and prediction. In addition, quite sophisticated transport models
have been developed for penetration into a solid tumor [19, 20, 21]. However, it is evident
that drug distribution from an internal injection has not been investigated mathematically.
Further, it is often the case that mathematical models describe either drug transport or
cell death, but seldom both. In this work we endeavor to build a new modeling framework
for injected drug distribution in solid tumors and its effect on tumor cell death, which we
hope will facilitate individualized treatment. This is done by producing the simplest possible
model in this framework, and laying bare the simplifying assumptions in order to open it to
scrutiny and improvement.
The remainder of the paper is organized as follows: we start by discussing the modeling
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procedure, the focus of the article, in Sec. 2 and 3. Section 2 contains the diffusion model for
drug distribution, and Sec. 3 relates the concentration profile from diffusion to cell death.
While the analytical solutions to the diffusion equation would generally be a linear combina-
tion of Bessel functions, since our initial condition is not a Bessel function a numerical code
would be required to match the coefficients of the Bessel functions. Instead we use finite
difference methods in Sec. 4 to numerically solve the equation from the start, and using this
solution for the concentration profile the cell death is computed. In Sec. 5 we compare our
dose-response curves with data points from experiments different from that of Morhard et
al. [13] since they did not include dose-response curves in their article. Furthermore, using
a different experiment shows the robustness of this type of modeling. Finally, we conclude
with a discussion about applying our modeling framework to individualized treatment in
Sec. 6.
2 Radially symmetric concentration diffusion model
In this section we derive the simplest possible model for drug diffusion in a tumor with leaky
boundaries where injection occurs at a much faster timescale than diffusion. First, let us
assume a spherical tumor with constant density. The drug concentration is given as the ratio
of the volume of the drug to that of the tumor. Since this is a diffusive process the initial
condition is taken as a compact Gaussian. Then the leak at the boundary is modeled as
“Newton’s law of cooling”[22]. Finally, we nondimensionalize the equation and conditions
to further simplify the model.
Consider the radially symmetric diffusion equation in spherical coordinates with constant
diffusivity
∂u
∂t
= D
(
∂2u
∂r2
+
2
r
∂u
∂r
)
(1)
where u is the concentration of the drug and D is the constant diffusivity. Since we are
injecting a volume into the center of the tumor (blue arrow in Fig. 2) and the diffusive
timescale is fast, it is reasonable to assume an initial compact Gaussian distribution (i.e., a
bump function) where the tail just reaches the boundary
u(r, t = 0) =
V0
Vb
{
exp
(
1− R2
R2−r2
)
for r < R,
0 for r ≥ R;
(2)
where R is the tumor radius, V0 is the injected volume, and Vb is the volume of the bump
function in spherical coordinates used for the purpose of normalization; that is,
V0 =
∫ pi
0
∫ 2pi
0
∫ R
0
u(r, t = 0)drdθdφ, when
Vb =
∫ pi
0
∫ 2pi
0
∫ R
0
exp
(
1− R
2
R2 − r2
)
drdθdφ
The generic bump function takes the 1-dimensional shape shown in Fig. 1, and by radial
symmetry this can be extended to 3-dimensions. At the boundary we know the drug leaks
3
Figure 1: A generic bump function with normalized height.
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due to the porosity of the tumor (red arrow in Fig. 2). However, diffusion in the tumor is
different from diffusion outside of the tumor. In fact, the tumor is far denser than healthy
cells, and therefore will hold onto the drug and let it accumulate as it leaks at a much
slower rate. We assume the drugs start leaking at the boundary of the tumor according to
“Newton’s law of cooling”[22],
D
∂u
∂r
∣∣∣∣
r=R
= −γu(r = R, t), (3)
where γ is the leak coefficient.
Figure 2: Diagram of the diffusion model where the blue arrow represents injection into the
tumor and the red arrow represents leakage out of the tumor. The tumor is illustrated as a
projection of the sphere into 2-dimensions.
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2.1 Nondimensionalization
In order to simplify the model and reduce the number of parameters into only the essential
relations we nondimensionalize the problem. The concentration u (ratio of drug volume to
tumor cell volume) is by definition nondimensional. Therefore, we need only do a change of
variables on t and r. Let rˆ = r/R and tˆ = t/T , which gives us the derivatives
∂
∂t
=
1
T
∂
∂tˆ
;
∂
∂r
=
1
R
∂
∂rˆ
⇒ ∂
2
∂r2
=
1
R2
∂2
∂rˆ2
.
Then our PDE becomes
∂u
∂t
=
DT
R2
(
∂2u
∂r2
+
2
r
∂u
∂r
)
,
and our initial condition becomes
u(rˆ, t = 0) =
Vˆ0
Vˆb
{
exp
(
1− R2
R2−rˆ2R2
)
for rˆ < R/R,
0 for rˆ ≥ R/R;
=
Vˆ0
Vˆb
{
exp
(
1− 1
1−rˆ2
)
for rˆ < 1,
0 for rˆ ≥ 1;
where Vˆ0 is the injected nondimensional volume and Vˆb is the volume of the nondimensional
bump function. Furthermore, the boundary condition becomes
D
R
∂u
∂r
∣∣∣∣
rˆ=1
= −γu(rˆ = 1, t)⇒ ∂u
∂r
∣∣∣∣
rˆ=1
= −Rγ
D
u(rˆ = 1, t) = −εu(rˆ = 1, t)
where ε = Rγ/D is the nondimensional leak coefficient. Removing the hats gives us the full
nondimensional problem
∂u
∂t
=
∂2u
∂r2
+
2
r
∂u
∂r
;
∂u
∂r
∣∣∣∣
r=1
= −εu(r = 1, t); (4a)
u(r, 0) =
V0
Vb
{
exp
(
1− 1
1−r2
)
for r < 1,
0 for r ≥ 1; (4b)
3 Relating concentration to cell death
Once we have a model for drug distribution, we may use it to analyze cell death. In biological
experiments this is done through dose-response curves (amount of drug administered vs
percent cell death at a specific time after administration) [23, 24]. The dose-response is
recorded by measuring the effect of a drug at various doses. A mathematical model allows
us to do the same, but for far more finely spaced doses and exposure times, thereby allowing
an observer to find an optimal treatment strategy for a specific individual.
While varying oxygen levels are a concern [25, 26, 27, 28], as a first approximation and
“proof of concept” model, we assume that the oxygen concentration throughout the tumor
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is constant for a given time. Therefore, the same amount of drug will kill a tumor cell no
matter where in the tumor it is. We define a drug concentration threshold that is required
to kill a cell for a given time, which is dependent on both the oxygen concentration and dose
strength.
Definition 1. The minimum concentration uT required to kill one cell after T hours is said
to be the concentration threshold of the tumor at time T .
Now we must relate the threshold uT to time explicitly in order to compare against
experimental data. Since log time is often used for time-response curves and time-dose-
response surfaces, we assume the threshold to be related to time in a negative exponential
manner, uT = a − b exp(−cT ). Employing the three most used time points in oncology,
T = 24, 48, 72, we solve for the constants at a fixed initial concentration to get
uT = a− be−cT ; a = u24u72 − u
2
48
u24 + u72 − 2u48 ; b =
(a− u24)2
a− u48 ; c =
1
24
ln
(
a− u24
a− u48
)
.
(5)
The plot of (5) is shown in Fig. 3.
Figure 3: Relation between time and concentration threshold from (5).
This allows us to produce dose-response curves at those three threshold values; i.e. curves
that go through those data points. Then the other data points are plotted at appropriate
concentrations.
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4 Numerical simulation of single-time dose-response
curve
In order to simulate the dose-response curves one must first solve (4). Since our problem
is radially symmetric, we may solve it on the spacial domain r ∈ [0, 1] by adding an addi-
tional “boundary” condition at the origin, namely ur(0, t) = 0. Although a Bessel function
solution can be found, matching it with the initial conditions in the model would not yield
analytical solutions, and it would be necessary to solve the integrals from the inner products
numerically. Therefore, we implement finite difference schemes to solve (4) instead of solving
for the constants in the Bessel function solution.
We compare the solutions from three stencils: Forwards in Time Centered in Space
(FTCS), Backwards in Time Centered in Space (BTCS), and Crank-Nicholson. For diffusion
problems, Crank-Nicholson is often used, however diffusion is only the base of our model, and
we often need to run diffusion 105 to 108 times for one plot, which renders Crank-Nicholson
inefficient. This application requires a fast, accurate, and stable solver. FTCS is certainly
fast, but it is at the mercy of the CFL condition [29]; i.e., we require ∆t/(∆x)2 ≤ 1/2. For
the videos illustrating the scheme we do not need high accuracy, but we do need a fast scheme
for high spatial resolution, so FTCS is employed. To produce the dose-response curves in
Sec. 5 we employ BTCS since it is not much slower than FTCS and almost as accurate as
Crank-Nicholson. This way we get high temporal resolution, which has the added benefit of
providing accurate dose-response curves, without sacrificing stability.
Once a solution for u from the finite difference schemes is obtained, the dose-response
curves can be plotted. As outlined in Sec. 3, in biological experiments the dose-response
is recorded by measuring the effect of a drug at various doses. In our model we implement
a threshold uT defined as the drug concentration required to kill a single cell. When the
concentration u is above this threshold on some interval r ∈ [0, rdeath], we may calculate the
volume of tumor death, which we assume eventually ablates. Dividing this volume by the
total nondimensional volume of 4pi/3 outputs the fraction of dead tumor cells, namely
Fraction of Dead Cells: Pdead :=
Volume Dead
Total Volume
=
4pir3death/3
4pi(r = 1)3/3
= r3death. (6)
This is demonstrated in Fig. 4. Where the concentration profile (blue curve) intersects the
threshold uT is the radius of cells killed after time T , which we denoted as rdeath.
There are three possible cases for the percent of the tumor that is killed, and hence
eventually ablated, at an exposure time of T : no ablation, partial ablation, and full ablation.
These are shown in Figs. 5-8.
In Fig. 5, the initial volume is so low that the height of the bump function does not
exceed the threshold. This provides and opportunity to calculate the least effective dose at a
given exposure time; i.e. when the height of the bump function is equivalent to the threshold
(illustrated in Fig. 6a). Notice that the height of the bump function (4b) at the center r = 0
is V0/Vb, where V0 is the initial volume and Vb is the volume of the bump function. If we let
8
Figure 4: Hypothetical concentration profile used to demonstrate percent tumor death cal-
culation. The blue curve represents the concentration profile of the drug, and the red dashed
line represents the concentration threshold required to kill a cell. The radius rdeath is taken
at the intersection of the two curves and is used to calculate the percent volume and hence
percent cell death.
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Figure 5: No ablation occurs, at time T , when the height of the initial profile is lower than
the threshold uT . This leads to an explicit formula for least effective dose shown in (7).
the height be uT then the least effective dose is
uLED = uT · Vb = uT 1
4pi/3
∫ pi
0
sinφdφ
∫ 2pi
0
dθ
∫ 1
0
exp
(
1− 1
1− r2
)
r2dr
= 3uT
∫ 1
0
exp
(
1− 1
1− r2
)
r2dr = 3
(
a− be−cT ) ∫ 1
0
exp
(
1− 1
1− r2
)
r2dr. (7)
From this analytical formula we may plot the least effective dose as a function of exposure
time in Fig. 6b. Furthermore, we observe that the steady-state least effective does is given
by
u∗LED = u∗ · Vb = 3 · a · Vb = 3
u24u72 − u248
u24 + u72 − 2u48
∫ 1
0
exp
(
1− 1
1− r2
)
r2dr. (8)
Figure 7 shows the death of a fraction of the tumor cells, and hence, by our initial
assumption, partial ablation. An exaggerated initial condition (Fig. 7a) is used to illustrate
the diffusion of the drug. In order to present a profile similar to that of (4b) (Fig. 7b),
we let the volume diffuse until the concentration at the boundary is above a small, but
appreciable, amount of u = 0.01. This is due to the discrepancy between diffusion in real
life, which happens in finite time, and mathematical diffusion, which occurs infinitely fast.
After a maximum radius of death is attained (Fig. 7c), the percent cell death is calculated
using the volume filled at this radius. After this maximum, the drug leaks out (Fig. 7d) and
eventually contributes to toxicity, which is left for a future study.
Finally, Fig. 8 shows complete tumor death for a threshold uT at a time T . As in Fig. 7,
an exaggerated initial condition (Fig. 8a) is used, and later a snapshot of a profile similar to
(4b) (Fig. 8b) is shown. Since the concentration in the entire tumor exceeds the threshold,
the entire tumor dies after a time T .
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(a) (b)
Figure 6: Least effective dose. (a) A sample profile illustrating the least effective dose. (b)
A sample relationship between the exposure time T and the least effective dose uLED. The
blue curve represents (7) and the stars mark the least effective doses for T = 24, 48, 72, and
96 hours.
(a) (b)
(c) (d)
Figure 7: Partial ablation at time T . An exaggerated initial condition was used in order
to illustrate the diffusion of the drug in (a), but the initial condition from the model (4) is
more like the profile in (b). (a) Exaggerated initial condition to illustrate the diffusion of
the drug. (b) Profile similar to that used for the initial condition in (4b). (c) Maximum
radius of effective concentration is attained. (d) The drug eventually leaks out contributing
to toxicity.
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(a) (b)
(c)
Figure 8: Full ablation at time T . (a) An exaggerated initial condition was used in order
to illustrate the diffusion of the drug in (a), but the initial condition from the model (4) is
more like the profile in (b). (a) Exaggerated initial condition to illustrate the diffusion of
the drug. (b) Profile similar to that used for the initial condition in (4b). (c) Full ablation
is attained, but just as in Fig. 7, the remainder of the drug will leak out and contribute to
toxicity.
Eventually all of the drug leaks out, but for the full ablation case the toxicity would
be higher than with partial ablation. Then we have a balancing act between efficacy and
toxicity. We may calculate the smallest dose required to kill the entire tumor at a time T
using the threshold uT , via the bisection method to find the initial concentration that allows
the entire concentration profile to be just over the threshold at the boundary, similar to a
shooting method. Since the diffusion and leak linear, we would expect the relation between
the threshold and smallest dose to be linear as well, which is precisely what we observe. If we
let ODi be the smallest does required to kill the tumor after a time Ti we get the following
relation between the ratios of the smallest dose and the respective threshold
OD1
OD2
=
uT1
uT2
. (9)
Since uT → u∗ as T → ∞, we may define an optimal steady-state dose as the smallest
dose required to kill the tumor assuming we wait infinitely long and the tumor growth is
completely inhibited. By this definition we notice that we may calculate OD for any time T
OD
OD∗
=
uT
u∗
⇒ OD = OD∗
u∗
uT =
[
a− be−cT ] OD∗
u∗
, (10)
which is precisely the modified Haber’s rule [30] because OD∗/u∗ is constant. In addition,
we may fix a threshold uT , and observe how the optimal dose for that threshold varies with
the nondimensional leak coefficient ε. We observe in Fig.9 that this relation, represented by
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the blue curve, is not linear although it may seem linear without the presence of the red
dashed line from the lowest to the highest point of the blue curve in that plot.
Figure 9: Relationship between the optimal dose OD for a given threshold uT = 0.25 and
the leak coefficient ε. The blue curve represents the optimal dose at the given threshold,
and the red dashed curve represents a straight line from the lowest point of the blue curve
to the highest demonstrating the nonlinearity of the optimal dose curve.
5 Comparison with clinical data
While there was no data on the rate of cell death in the study by Morhard et al. [13] be-
cause it focused on tumor shrinkage, we may use other clinical/experimental data sets to
show qualitative agreement. This would indicate the modeling framework is reasonable, and
then the models may be modified for different applications. In this light, a “proof of concept”
comparison is made between the model and a sample data set obtained from LINCS database
(http://lincs.hms.harvard.edu/db/) which, among other things, offers cellular responses to
chemical and genetic pertubations. In this article we consider apoptosis fraction as the cel-
lular response observed under different dosage of different compounds. So, our experimental
data consists of a set of dose-response pairs observed for several cell- lines and compounds
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at 24, 48 and 72 hours. The dose-response curves from the model and the observed data
points are shown in Fig. 10.
By employing (5) we find the concentration thresholds at the three time points for a given
initial drug concentration. For the dose-response curves in this article we match an initial
dose of 1µM to an initial concentration of 1/12 tumor volume because the experiments of
Morhard et al. [13] showed complete ablation for all of their hamsters at 1/4 tumor volume,
which is approximately what would be achieved by most of the cell line - drug pairs if the 72
hour time point response is extrapolated to 1/4 tumor volume. Furthermore, we match two
other doses by varying the initial volume until the distance between two of the three time
points is minimized. We choose to match two time points since it is evident that the data set
is quite noisy and it has outliers that do not obey the Hill equation [23]. One concern may
be the nonuniformity of the initial volume - dose relation, but this is to be expected since
the relation is dependent on the tumor size and concentration of the drug in the solution.
In this section, using a leak coefficient of ε = 5, we illustrate our performance in modeing
the apoptosis fraction observed for cell line “C32” and drug “Selumetinib”(we offer a few
more illustrative performances in Appendix A. Since the data is quite noisy for low doses a
truncated data set, shown in Table 1, is much more reliable for comparisons with the model.
The responses for a dose of 1µM from the pair is matched with 1/12 tumor volume from
the model. Equation 5 gives us the relation between the three time points (24, 48, and 72
hours) and the thresholds (u24, u48, and u72). These thresholds are then used to produce
the simulated dose-response curves in Fig. 10. The data from the 1µM dose will match
up exactly with the curves. In order to match the data from the 0.316µM and 3.16µM
doses with the respective initial concentration in the model we identify the concentration for
which the difference between the response in the data and the model of two time points is
minimized. For example, in Fig. 10, the 0.316µM dose corresponds to an initial concentration
of approximately 1/20 of the tumor volume since the 72 hour and 48 hour time points are
closest to the curve at that dose, and similarly the 3.16µM corresponds to approximately
7/50 of the tumor volume since the 72 hour and 24 hour time points are closest. Since
72 hours is near the steady state of this process, the curves often match the data at that
time point. For the 24 and 48 hour time points, the data becomes quite noisy with outliers
and responses that would not be possible to achieve, indicating possibly large errors. If the
distance between all three points were minimized, these outliers would have a stronger effect.
Table 1: Truncated data set for cell line “C32” with drug “Selumetinib”
Dose (micromole) Time (hours) Response (apoptosis fraction)
0.316
24 0.2148
48 0.262
72 0.4026
1.000
24 0.2365
48 0.5982
72 0.7591
3.160
24 0.2716
48 0.8303
72 0.8621
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Figure 10: Simulated dose-response curves for cell line “C32” and drug “Selumetinib” com-
pared to experimental data points (stars). The blue curves and markers are at 24 hours, red
is 48 hours, and black is 72 hours.
Besides the foregoing three dose points we assume that at a dose of zero the response
should be around zero. Once we match the original concentration levels with the tumor
volumes, we empirically fit a sigmoidal curve to the experimental dose-response data observed
at 72 hours. The empirical model is given by
Apoptosis fraction = a+
d
1 +
(
δ
concentration
)θ (11)
where a is the lower asymptote of the response curve, d is the range of response, δ is typically
interpreted as EC50 and θ is the Hill coefficient. The parameters of the Hill equation (11) are
estimated using non-linear least squares fit. We then generate 50 replicates from the fitted
sigmoid curve using parametric bootstrap procedure with errors drawn from a Gaussian
process with exponential correlation function. The noise variance is comparable to the
residual variance obtained from the least square fit (11) and the range parameter is chosen
to ensure smoothness and monotonicity of each replicate. Fig. 11 shows 50 bootstrap
replicates for cell line “C32” and drug “Selumetinib”.
From these bootstrap replicates of sigmoidal curves we compute the point-wise 95% con-
fidence intervals at each matched dose, then join them into a piece-wise linear approximate
confidence band. An example of this is shown in Fig. 12 for the foregoing illustrative case.
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The dose-response curve produced by our model is represented as the black curve, and the
point-wise empirical quantiles are connected by the piece-wise linear dashed curves. Observe
that the curve produced by our model is contained within the 95% pointwise confidence
interval, indicating statistical adequacy of the the deterministic model. The remainder of
the data pairs are relegated to Appendix B.
We would like to point out that since we are computing pointwise confidence intervals,
there could be situations where for some dose levels our model output lies outside the 95%
confidence interval computed at those doses. Rare occurrences (less than 5% of the times)
of such instances do not necessarily indicate statistical inadequacy of the posited model.
However, frequent occurrences of such events (more than 10% of the times) do indicate
statistical inadequacy.
Figure 11: Fifty sigmoidal curves fitting the empirical data, which is given a Gaussian spread
to simulate error at each dose point, for cell line “C32” and drug “Selumetinib” at 72 hours
of exposure time.
Given the empirical evidence that our model is statistically adequate to generate dose-
response curves from experimental data, we proceed to compute the theoretical EC50s for
this dataset. The model is cut off at the maximum empirical response, and the EC50s,
by definition, are computed as the dose to achieve half that response. We use a bisection
scheme similar to that of the optimal dose. EC50s are then approximated within a maximum
response error of |uapprox−u(EC50)| < 0.0025. The spatial resolution of the diffusion scheme
will limit the error bound, so this must be chosen to be equivalent or less than the desired
16
Figure 12: Theoretical dose-response curve for cell line “C32” and drug “Selumetinib” within
a 95% confidence band at 72 hours of exposure time. The black curve represents the dose-
response from the model. The blue and red dashed lines represent the piece-wise linear curve
connecting the lower and upper quantiles of each of the 95% confidence intervals.
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error. Table 2 shows the theoretical EC50s and the associated errors.
Table 2: Theoretical EC50s with response errors
Cell line Drug EC50 Response error
C32
SB590885 0.0562 0.0006
PLX-4720 0.0684 0.0015
AZ-628 0.0596 0.0007
Selumetinib 0.0596 0.0007
Vemurafenib 0.0840 0.0017
COLO 858
SB590885 0.1055 0.0015
PLX-4720 0.1260 0.0005
AZ-628 0.0830 0.0019
Selumetinib 0.1035 0.0014
RVH-421
AZ-628 0.1191 0.0013
Selumetinib 0.1221 0.0002
WM-115
SB590885 0.1074 0.0021
AZ-628 0.0664 0.0008
M27-mel
SB590885 0.1191 0.0024
PLX-4720 0.0664 0.0008
AZ-628 0.0908 0.0003
Selumetinib 0.1006 0.0007
Vemurafenib 0.1230 0.0023
While a dose-response curve may be easily fit to the empirical data, a reliable dose-time-
response surface is much more difficult due to how noisy the data is. With a mechanistic
model we get a full dose-threshold-response surface (Fig. 13), which can be turned into an
individual’s dose-time-response surface by using (5) in Sec. 3 to relate the threshold to time.
We observe that the surface in Fig. 13 is qualitatively similar to that of Miller et al. [30],
further solidifying the agreement between this new model and previous studies.
6 Conclusion
Cancer treatments have come a long way in terms of their increased efficacy and reduced
toxicity. However, it is still very much a “trial and error” process. Since individuals contain
such a variety of biological properties, and in fact separate tumors in the same individual
are also quite different, we need to develop better individualized treatments. While there
is an abundance of statistical models [4], there are few mechanistic models detailing the
distribution of drugs inside a tumor leading to tumor cell death. There has been recent work
on transport models for drugs into solid tumors [17, 18, 19, 20, 21], but there are no models
in the literature that describe the diffusion from an injection into a solid tumor causing it
to ablate.
In this investigation we developed a radially symmetric concentration diffusion model in
a solid spherical tumor with leaky boundaries in Sec. 2, which is then nondimensionalized
to absorb the constants (radius, diffusivity, leak coefficient) into the nondimensional leak
18
Figure 13: Simulated dose-threshold-response surface. This can be converted into a dose-
time-response surface by calibrating (5) in Sec. 3 the time-threshold relation for each cell
line and drug.
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coefficient, effectively making it a one parameter model. Then in Sec. 3, the concentration
from the diffusion model is related to cell death assuming a fixed constant concentration
required to kill a cell at a time T , which we call the concentration threshold, uT . Three
time points, at a specific initial dose, are used to relate the threshold to time using (5).
Numerical simulations used to produce dose-response curves are described in Sec. 4, and
the curves themselves are illustrated in Sec. 5, where they are tested against empirical data.
While [13] did not include dose-response curves in their study, we use a different empirical
data set to show qualitative agreement and use it as a “proof of concept” comparison. The
comparison with a completely different data set solidifies the argument that this is a modeling
framework that can be applied to other experiments and not just a model for the Morhard
et al. experiments [13].
It is true that, due to its simplicity, the model presented here misses some of the behavior
associated with the diffusion of a drug leading to cell death. Critics may even suggest that it
is na¨ıve. It is completely legitimate to call into question the assumption that the tumor is a
uniformly dense sphere (i.e., constant diffusivity and radial symmetry). One may also point
to the use of a constant (in space, but not in time) concentration threshold for the death of
a tumor cell since oxygen availability varies in the tumor [25, 26, 27, 28]. However, scrutiny
is precisely what we seek because this will lead to more sophisticated models, but these will
still be in the framework of drug diffusion inside a solid tumor leading to tumor cell death,
and eventually ablation. We shall endeavor to develop more models in this framework, and
we hope that other researchers will as well.
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A Dose-response curves
Here we present the remainder of the dose-response plots from Sec. 5. For each of the
curves, an initial dose of 1µM is mapped to an initial concentration of 1/12 tumor volume.
Equation 5 gives us the relation between the three time points (24, 48, and 72 hours) and
the thresholds (u24, u48, and u72). These thresholds are then used to produce the simulated
dose-response curves in Fig. 14. Then the two other initial doses are matched by varying the
dose until a minimum distance between two of the time points and the curves is achieved.
We choose to match two time points since it is evident that the data set is quite noisy and
it has outliers that do not obey the Hill equation [23].
B Confidence bands
In this appendix, we present the remainder of the confidence band plots from Sec. 5. For
each of the curves, an initial dose of 1µM is mapped to an initial concentration of 1/12
tumor volume. Equation 5 gives us the relation between the three time points (24, 48, and
72 hours) and the thresholds (u24, u48, and u72). Then three other initial doses are matched
by varying the dose until a minimum distance between the 72 hour time point and the curves
is achieved. We choose to study the 72 hour time points since the least amount of noise is
observed at this exposure time and therefore more closely matches the Hill equation [23].
We need one extra point in order to fit a four parameter sigmoidal curve to the empirical
data points. Notice that at an initial dose of zero the response must be around zero, and
hence we use that point as well. Using a bootstrap scheme, fifty sigmoidal curves fitting the
data, with a prescribed probability spread at each dose point, are produced (shown in Fig.
11 in Sec. 5). These curves give us an artificial replication study. From the curves we find
the 95% confidence intervals at each matched dose point, and connect a piece-wise linear
curve to the lower and upper quantiles of these intervals, which yields a confidence band.
Then the dose-response curves from the model are plotted. Since the data set is quite noisy
for low initial doses, not every data pair would fit a sigmoidal curve, but many did in fact
work as shown in Fig. 15.
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Figure 14: Matrix of dose-response curves from the entire data set. The columns denote
the drugs and the rows denote the cell lines for the data pairs. Dose-response curves are
produced in accordance with the techniques delineated in Sec. 5.
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Figure 15: Matrix of dose-response curves within 95% confidence bands. The columns denote
the drugs and the rows denote the cell lines for the data pairs. Dose-response curves are
produced in accordance with the techniques delineated in Sec. 5.
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